•  Today I will take
  • my stem cells to the bank.
  • Thomas Fowell (38), Asset Manager
  •  I'm glad there is a bank
  • where I can invest
  • my health profitably.
  • Michelle Li (35), Sales Manager Beauty/Kosmetik
  •  I have put aside something
  • for the future: my stem cells
  • Sammo Yeng (39), CEO

TICEBA is a highly innovative German bio-pharmaceutical Life-Science Company, which operates in the fields of stem cell research and regenerative medicine. As the world's first private tissue bank, the German company offers its clients the removal and storage of the cells from the skin and the stem cells contained therein as personal, biological life insurance and has established itself as a pharmaceutical active ingredient manufacturer for stem cell-based therapies.


TICEBA Creation of a unique biological life insurance
Production: July 2014


TICEBA corporate video Back-up Your Life!
Production: September 2011

News
Clinical Trial - EB

The trial has been approved by the U.S. Food and Drug Administration (FDA) and the other respective competent national regulatory authorities and has recently been granted Orphan Drug Designation for the treatment of RDEB in the EU and the USA.

Clinical Trial - LSCD

For the international and FDA approved clinical trial for the limbal stem cell medicinal product LSC2 our daughter company RHEACELL recently received Orphan Drug Designation status in the EU for the treatment of limbal stem cell deficiency (LSCD) and Fast Track Designation in the USA. More information can be found HERE and HERE.

Clinical Trials

Our subsidiary RHEACELL is recruiting patients for further clinical trials in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the indications chronic venous ulcers (CVU), diabetic foot ulcers (DFU), peripheral arterial occlusive disease (PAOD), epidermolysis bullosa (EB) and acute on chronic liver failure (ACLF) and with allogeneic ABCB5+ limbal stem cells for the indication limbal stem cell deficiency (LSCD). For more information click HERE.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter